- Updated patient-reported outcomes from the CROWN study: Analyses in first-line ALK plus patients with (w) and without (w/ o) baseline brain metastases (BMs) and w or w/o central nervous system adverse events (CNS AEs)Liu, G.; Zhou, Q.; Solomon, B. J.; Le, H.; Reisman, A.; Thomaidou, D.; Toffalorio, F.; Mazieres, J.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.
- ALINA: Efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK plus non-small cell lung cancer (NSCLC)Solomon, B. J.; Ahn, J. S.; Dziadziuszko, R.; Barlesi, F.; Nishio, M.; Lee, D. H.; Lee, J. S.; Zhong, W. Z.; Horinouchi, H.; Mao, W.; Hochmair, M. J.; De Marinis, F.; Migliorino, M. R.; Bondarenko, I.; Lohmann, T. O.; Xu, T.; Gavaldon, A. Cardona; Bordogna, W.; Ruf, T.; Wu, Y. L.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), Barcelona, SPAIN, 2023-10-20 To 2023-10-24.被引 3
- SURVIVAL BENEFIT OF RADIOTHERAPY AND SURGERY IN PATIENTS WITH LUNG CANCER BRAIN METASTASES WITH POOR PROGNOSIS FACTORSLiang, L.; Wang, Z.; Duan, H.; Lu, J.; Jiang, X.; Hu, H.; Li, C.; Yu, C.; Zhong, S.; Cui, R.; Guo, X.; He, Z.; Chen, L.; Mou, Y.
会议论文
Management of patients with ALK-positive advanced non-small cell lung cancer who received brain radiotherapy on study in the phase 3 CROWN trial
3阅读
